Jpmorgan Chase & CO Nu Cana PLC Transaction History

Jpmorgan Chase & CO

  • $1.22 Trillion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Dec 26, 2024
BUY
$0.26 - $0.42 $0 - $0
1 New
1 $0
Q1 2024

May 10, 2024
BUY
$0.26 - $0.42 $0 - $0
1 New
1 $0
Q2 2022

Aug 11, 2022
SELL
$0.59 - $1.06 $6,509 - $11,694
-11,033 Closed
0 $0
Q1 2022

May 11, 2022
BUY
$0.74 - $3.27 $8,164 - $36,077
11,033 New
11,033 $11,000

Others Institutions Holding NCNA

# of Institutions
1
Shares Held
3.33M
Call Options Held
0
Put Options Held
0
View Full List

About NuCana plc

NCNA Quotes by TradingView
  • Ticker NCNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,196,000
  • Market Cap $59.5M
  • Description
  • NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients ...
More about NCNA
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email